Loading
ETS2 (ETS proto-oncogene 2, transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.
Transcription factor activating transcription. Binds specifically the DNA GGAA/T core motif (Ets-binding site or EBS) in gene promoters and stimulates transcription.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Paclitaxel and Cisplatin.
In plain words · ETS2 (ETS proto-oncogene 2, transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.
ETS2 (ETS proto-oncogene 2, transcription factor) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-small-cell lung cancer.
Transcription factor activating transcription. Binds specifically the DNA GGAA/T core motif (Ets-binding site or EBS) in gene promoters and stimulates transcription.
No product in this corpus aims at ETS2 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA ETS2: RNA low tissue specificity; blood lineage group enriched (dendritic cells 34 nTPM, granulocytes 37 nTPM, monocytes 33 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Lung cancer (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas ETS2 tissue; Open Targets ENSG00000157557 associations
First described 1985. Earliest sequence paper UniProt cites for the protein: Watson D.K. et al, Proc. Natl. Acad. Sci. U.S.A, 1985, "The ets sequence from the transforming gene of avian erythroblastosis virus, E26, has unique domains on human chromosomes 11 and 21: both loci are transcriptionally active". Source.
Sources: HGNC HGNC:3489 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P15036 (protein name, function text, keywords and locations (REST API)); CIViC gene ETS2 (1 evidence items, 0 assertions, 1 variants; diseases: Lung Non-small Cell Carcinoma (GraphQL API, CC0))
Transcription factor activating transcription. Binds specifically the DNA GGAA/T core motif (Ets-binding site or EBS) in gene promoters and stimulates transcription. Location: Nucleus (UniProt). Locus 21q22.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues. Blood: group enriched (dendritic cells 34 nTPM, granulocytes 37 nTPM, monocytes 33 nTPM).
No normal tissue stained high.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ETS2" OR ABSTRACT:"ETS2" OR TITLE:"ETS proto-oncogene 2, transcription factor" OR ABSTRACT:"ETS proto-oncogene 2, transcription factor") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ETS2, not a curated reading list.